




RealRate

PHARMACEUTICAL 2020

NEXIEN BIOPHARMA INC.

Rank 362 of 362



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2020

NEXIEN BIOPHARMA INC. Rank 362 of 362

The relative strengths and weaknesses of NEXIEN BIOPHARMA INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NEXIEN BIOPHARMA INC. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 2,333% points. The greatest weakness of NEXIEN BIOPHARMA INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 8,601% points.

The company's Economic Capital Ratio, given in the ranking table, is -9,661%, being 9,358% points below the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	311
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	45
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	568
Other Liabilities	0
Other Net Income	0
Property and Equipment	0
Research and Development	64
Revenues	0
Selling, General and Administrative Expense	3,669

Output Variable	Value in 1000 USD
Assets	311
Liabilities	45
Expenses	4,301
Stockholders Equity	266
Net Income	-4,301
Comprehensive Net Income	-4,301
Economic Capital Ratio	-9,661%

